82 results
Page 2 of 5
6-K
EX-99
ul8db
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am
6-K
EX-99
38sk oiy1sqo0hj13dd
18 Nov 20
BioLineRx Announces Initiation of Phase 1b Clinical Trial
7:09am
424B5
ona39mp
13 Nov 20
Prospectus supplement for primary offering
4:31pm
424B5
21k62nl2
25 Sep 20
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
8zzzlrcd32r7
19 Aug 20
BioLineRx Achieves Enrollment Target in Phase 3
7:08am
6-K
EX-99
einf37hhzn okb3x
6 Aug 20
BioLineRx Reports Second Quarter 2020 Financial Results
7:47am
6-K
EX-99
epy4oyuqbuzb csm8
6 Aug 20
BioLineRx Reports Second Quarter 2020 Financial Results
7:47am
6-K
EX-99
czuc6j7uq6vo
6 Aug 20
BioLineRx Reports Second Quarter 2020 Financial Results
7:47am
6-K
EX-99
v0k636o y3thxgcuoof
20 May 20
BioLineRx Reports First Quarter 2020 Financial Results
7:00am
6-K
EX-99
20ntgwcyr3urw
20 May 20
BioLineRx Reports First Quarter 2020 Financial Results
7:00am
6-K
EX-99
6g53o9r
12 Mar 20
BioLineRx Reports Year-End 2019 Financial Results
7:00am
6-K
EX-99
xtl57c06
27 Feb 20
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination with The COMBAT/KEYNOTE-202 Study
7:00am
6-K
EX-99
uix ovaxef1w89p3l
22 Jan 20
BioLineRx Completes Recruitment in Triple Combination
7:00am
6-K
EX-99
qkq4yy67vxtxkh5vs
13 Dec 19
BioLineRx Announces Updated Phase 2a Data from Triple
7:00am
6-K
EX-99
5lvy8z578lh6 fd1hve
6 Aug 19
BioLineRx Reports Second Quarter 2019 Financial Results
7:11am
20-F/A
EX-4.40
7mqrc4oq98e
31 May 16
Annual report (foreign) (amended)
12:00am